2-Benzyl 4-Ethyl 4,8,8-Trimethyl-6,10-dioxa-2-azaspiro[4.5]decane-2,4-dicarboxylate | 309762-64-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 2-Benzyl 4-Ethyl 4,8,8-Trimethyl-6,10-dioxa-2-azaspiro[4.5]decane-2,4-dicarboxylate
• 英文别名: 2-O-benzyl 4-O-ethyl 4,8,8-trimethyl-6,10-dioxa-2-azaspiro[4.5]decane-2,4-dicarboxylate
• CAS: 309762-64-9
• 化学式: C₂₁H₂₉NO₆
• 分子量: 391.464
• InChiKey: ZONAGMRZBMQZRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  74.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-Benzyl 4-Ethyl 4,8,8-Trimethyl-6,10-dioxa-2-azaspiro[4.5]decane-2,4-dicarboxylate 在 palladium on activated charcoal lithium aluminium tetrahydride 、 sodium azide 、 水 、 氢气 、 potassium carbonate 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 11.5h， 生成 2-benzyl-4-aminomethyl-4,8,8-trimethyl-6,10-dioxa-2-azaspiro[4.5]decane
  参考文献：
  名称：

  Syntheses and biological evaluation of new fluoroquinolone antibacterials containing chiral oxiimino pyrrolidine

  摘要：

  The design and syntheses of new fluoroquinolone antibacterial agents having pyrrolidine ring at C-7 position are described. The pyrrolidine ring is optically active and possesses methyloxime functional group. Two of them have excellent in vitro antibacterial activities and pharmacokinetic profiles. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.044
• 作为产物：
  描述：

  N-Cbz-4-氧代-3-吡咯烷甲酸乙酯 在 potassium carbonate 、 对甲苯磺酸 作用下， 以 正庚烷 、 丙酮 为溶剂， 反应 9.0h， 生成 2-Benzyl 4-Ethyl 4,8,8-Trimethyl-6,10-dioxa-2-azaspiro[4.5]decane-2,4-dicarboxylate
  参考文献：
  名称：

  Syntheses and biological evaluation of new fluoroquinolone antibacterials containing chiral oxiimino pyrrolidine

  摘要：

  The design and syntheses of new fluoroquinolone antibacterial agents having pyrrolidine ring at C-7 position are described. The pyrrolidine ring is optically active and possesses methyloxime functional group. Two of them have excellent in vitro antibacterial activities and pharmacokinetic profiles. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.044

文献信息

• Optically active quinoline carboxylic acid derivatives with 7-pyrrolidine substituents causing optical activity and a process for the preparation thereof
  申请人：Dong Wha Pharm. Ind. Co., Ltd.

  公开号：US06649763B1

  公开（公告）日：2003-11-18

  The present invention relates to optically active quinoline carboxylic acid derivatives, their pharmaceutically acceptable salts, their solvates, and a process for the preparation thereof. More specifically, the present invention relates to optically active quinoline carboxylic acid derivatives containing 4-aminomethyl-4-methyl-3-(Z)-alkoxyirninopyrrolidine substituents causing optical activity at the 7-position of the quinolone nuclei. As the compounds of the present invention have superior antibacterial activity and pharmacokinetic profiles to their enantiomers, their racemates and conventional antibacterial agents, with nearly no phototoxicity, the compounds of this invention are useful for antibacterial agents.

  本发明涉及具有光学活性的喹啉羧酸衍生物、其药学上可接受的盐、溶剂合物及其制备方法。更具体地，本发明涉及含有4-氨基甲基-4-甲基-3-(Z)-烷氧亚氨基吡咯烷取代基的具有光学活性的喹啉羧酸衍生物，该取代基在喹啉核的7位引起光学活性。由于本发明的化合物相对于其对映体、消旋体和常规抗菌剂具有优越的抗菌活性和药代动力学特性，且几乎没有光毒性，因此本发明的化合物可作为抗菌剂使用。
• OPTICALLY ACTIVE QUINOLINE CARBOXYLIC ACID DERIVATIVES HAVING 7-PYRROLIDINE SUBSTITUTES CAUSING OPTICAL ACTIVITY AND A PROCESS FOR PREPARING THEREOF
  申请人：DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD.

  公开号：EP1187835B1

  公开（公告）日：2007-12-26
• US6753430B2
  申请人：——

  公开号：US6753430B2

  公开（公告）日：2004-06-22
• Syntheses and biological evaluation of new fluoroquinolone antibacterials containing chiral oxiimino pyrrolidine
  作者：Dong Rack Choi、Jung Han Shin、Jin Yang、Sue Hye Yoon、Yong Ho Jung

  DOI：10.1016/j.bmcl.2003.12.044

  日期：2004.3

  The design and syntheses of new fluoroquinolone antibacterial agents having pyrrolidine ring at C-7 position are described. The pyrrolidine ring is optically active and possesses methyloxime functional group. Two of them have excellent in vitro antibacterial activities and pharmacokinetic profiles. (C) 2003 Elsevier Ltd. All rights reserved.